DTC/DTP + Telemedicine – The Next Big Thing in Pharma?
How should pharma leaders adapt to this new DTC/DTP-driven world, and what role does telemedicine play in closing the loop from awareness to access?
DTC/DTP + Telemedicine: The Next Big Thing in Pharma?
Archbow Consulting recently partnered with Omnicom Health to raise awareness about a buzz-worthy case study examining the recent trend of Direct-to-Consumer (DTC) and Direct-to-Patient (DTP) models—and what these shifts mean for the future of the pharmaceutical industry.
Discover how DTC/DTP and telemedicine are transforming healthcare access. Dive into real-world insights on digital health solutions, improved patient outcomes, and the evolving landscape of care delivery. Read the full case study here.
For additional insights on this topic, you may also enjoy the following:
Mastering 3PL Economics for Manufacturers
Discover how specialized 3PL cost analysis helps manufacturers identify pricing discrepancies and negotiate with confidence.
Preparing for the FDA’s 12-Digit NDC Transition
Manufacturers should begin planning early to assess impacts, align stakeholders, update affected processes, and allow sufficient time for testing and implementation before the March 7, 2033 deadline.
Is Your Specialty Distribution Fee Schedule Keeping Pace?
Specialty distribution fee schedules must evolve with market conditions and service requirements. Archbow provides benchmarking, FMV analysis, and negotiation support to help manufacturers establish informed, defensible agreements.
SUBSCRIBE
Subscribe to receive news and updates from Archbow Consulting
|
|


